SIRION Biotech Plans Opening of a New Office in the Boston Area
Boston, MA and Munich, Germany, June
17, 2015 – SIRION Biotech, a leading viral vector platform
company known for creating high quality viral vector solutions for industry and
academic partners, today announced its commitment to open a new office in the
vicinity of Boston. The announcement was made during the 2015 BIO
International Convention taking place this week in
Philadelphia, Pennsylvania.
SIRION is working with the Massachusetts
Life Sciences Center (MLSC) to
locate lab and office space for the Company, which will prove to be a pivotal
step in SIRION’s U.S. expansion. SIRION’s office in the Boston area will allow
direct access to Massachusetts’ vibrant life science community, which includes
an increasing number of biotechnology companies and academic researchers
working to develop gene therapies and vaccines for a range of diseases.
“We appreciate the assistance from
Massachusetts Life Sciences Center in helping us begin building our U.S.
operations in the Boston area, during such an exciting time in our industry,”
said Dieter Lingelbach, Chief Operating Officer of SIRION Biotech. “We are a
growing company, planning to build on the success we’ve had in Europe, Israel
and Japan, as we collaborate with many companies pioneering gene therapies.”
“We are pleased to welcome SIRION to
Massachusetts, where the gene therapy space continues to receive significant
attention from stakeholders in the life sciences due to its potential to cure a
variety of diseases,” said Angus McQuilken, MLSC Vice President for
Communications & Marketing. “SIRION will be a great addition to this
growing part of the Massachusetts life sciences ecosystem.”
"We're so excited to welcome
SIRION to the Massachusetts super cluster and know it is going to hit the
ground running as a valuable partner to the companies and organizations here,”
said Robert K. Coughlin, President and CEO at MassBio.
SIRION provides customizable versions
of all three major viral vector types, adenovirus (AV), adeno-associated virus
(AAV) and lentivirus (LV), and offers expertise in transduction of various cell
lines, an essential piece of all genetic applications. SIRION’s high quality
products and well established processes coupled with its commitment to
addressing each client’s unique needs, has established the Company as a leader
in viral vector solutions. SIRION’s expertise in custom viral vector solutions
and process development makes SIRION an ideal collaborative partner.
“Producing products of the highest
quality, purity and yield are of paramount importance and is also one of the
biggest challenges,” said Dr. Christian Thirion, Founder and CTO. “Our suite of
proprietary products and services enables us to provide the highest quality
tools for downstream applications in gene therapy and vaccine development.”
"I am very pleased that our work to attract life sciences investment - particularly in viral vector manufacturing - is evident to companies like Sirion,” said Senator Michael Rodriques (D-Westport). “This is a great opportunity for Massachusetts, and during our meeting with the company I spoke to them about all that Fall River has to offer as a potential location for this growing company's U.S. operations."
沒有留言:
發佈留言